GTCbio and the advisory board would like to invite you to the 11th Diabetes Summit to be held April 10-11, 2018 in Boston, MA. GTCbio’s Diabetes Summit encompasses the drug discovery and partnering aspects of diabetes in three tracks.. Experts from industry and academia will discuss strategies to target Type 1 and Type 2 diabetes in presentations, panels and round-table discussions that highlight basic research novel therapeutic targets, translation to the clinic, devices and digital aids, funding and partnering trends, emerging technologies and other relevant topics.
Joint Plenary Sessions:
- Opening Keynote Session – Historical Perspective & State of the Industry
- Round Table Discussions
- Ready, Set, Grow – New Company/Technology Pitch Competition & Lunch
- Award Ceremony & Closing Keynote Session – Predictions for future
Track 1: Diabetes Drug Discovery & Development for Type I Diabetes
- What’s New in Type I Diabetes – Targets, Models, Assays, etc.
- Translational and Clinical Development for Type I Diabetes
Track 2: Diabetes Partnering & Deal-Making Conference
- Industry Partnering with Academia and CROs to Advance Research
- Investments from Private, Institutional and Public Sources
Track 3: Diabetes Drug Discovery & Development for Type II Diabetes
- What’s New in Type II Diabetes – Targets, Models, Assays, etc.
- Translational and Clinical Development for Type II Diabetes
Track 4: Devices and Digital Aids in Diabetes Management Conference
- Next Generation Glucose Monitoring Devices and Technology
- The Role of “Being Digitally Connected” in Diabetes Management
We look forward to seeing you at the conference!
The 2018 Advisory Committee
|2018 Advisory Board Members|
|Robert Geho, Diasome Pharmaceuticals Inc|
|Zan Fleming, Kinexum|
|Alan Cherrington, Vanderbilt|
|Brian T. Bloomquist, Eli Lilly|
|Aaron Schwartz, Novo Nordisk|
|Riccardo Perfetti, Sanofi Diabetes & Cardiovascular Business Unit|
|Nandan Padukone, Joslin Diabetes Center|
|Nathaniel Heintzman, Dexcom|
|Vivek Shenoy, Renovo Neural|
|Judith Gorski, Crown Bioscience|
|Vijay Koya, Boston Scientific|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
BioSpherix will be exhibiting the Xvivo System, world's first and only cytocentric barrier isolator optimized for cells. Economical and practical alternative to cleanrooms for cGMP compliant production of cells for clinical use. Get better contamination, process and quality control. Stop by BioSpherix booth to learn more about the only total quality platform for cells!
Viracor Eurofins provides clinical trial biomarker testing services with expertise in custom assay transfer, design and validation for phase I-IV trials. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing.
Merck has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. We're pursuing some of the most innovative areas in biomedical research emerging today without regard to therapeutic area/modality. Merck has hundreds of successful collaborations with companies, academic institutions, and other organizations. Learn more at www.merck.com/licensing.
CBSET is a not-for-profit translational research institute specializing in the evaluation of drugs, biotherapeutics, combination products, and medical devices. We provide preclinical services including in-life testing, histopathology and regulatory consulting. Our GLP-compliant facilities host a multidisciplinary team of medical, scientific and regulatory experts who actively collaborate in getting novel technologies to market.